Sugi Predict

Sugi Predict / Compounds / SCHEMBL15076534

SCHEMBL15076534

SCHEMBL15076534

O=C(Nc1ccc(F)c(F)c1)c1cccc(S(=O)(=O)N2CCC(O)CC2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.73
▸ MEN1 O00255 3/20 0.73
▸ CYP3A4 P08684 1/20 0.60
▸ CYP2D6 P10635 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ KCNH2 Q12809 1/20 0.60
▸ CASP1 P29466 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ CNR1 P21554 1/20 0.58
▸ ALDH1A1 P00352 2/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ GAA P10253 2/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ HTR2B P41595 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ SIRT2 Q8IXJ6 1/20 0.55
▸ MAPK1 P28482 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15076347 0.94 KMT2A (0.67) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL15276888 0.92 MEN1 (0.62) KMT2AMEN1CASP1HTTHSD17B10
SCHEMBL15276890 0.92 KMT2A (0.62) KMT2AMEN1CASP1HTTHSD17B10
SCHEMBL15276930 0.91 KMT2A (0.61) KMT2AMEN1CASP1HTTHSD17B10
SCHEMBL15276887 0.91 KMT2A (0.63) KMT2AMEN1CASP1HTTHSD17B10
SCHEMBL15276889 0.90 KMT2A (0.59) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL15076769 0.90 CYP1A2 (0.62) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL15276841 0.89 KMT2A (0.69) KMT2AMEN1CASP1HTTHSD17B10
SCHEMBL15276882 0.89 SMN1; SMN2 (0.61) KMT2AMEN1CASP1HTTHSD17B10
SCHEMBL15076326 0.89 KMT2A (0.59) KMT2AMEN1CASP1HTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3312160-B1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS INC (US) 2020-03-18 — — EP disclosed
US-10196376-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2019-02-05 — — US disclosed
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC 2017-11-23 — — US disclosed
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC 2017-11-23 — — US disclosed
US-9751857-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-09-05 — — US disclosed
US-9751857-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-09-05 — — US disclosed
EP-2794565-B1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS INC (US) 2017-07-26 — — EP disclosed
US-9676747-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-06-13 — — US disclosed
US-9676747-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-06-13 — — US disclosed
US-20150259324-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2015-09-17 — — US disclosed
US-20150152073-A1 Hepatitis B Antiviral Agents NOVIRA THERAPEUTICS, INC. 2015-06-04 — — US disclosed
US-20150152073-A1 Hepatitis B Antiviral Agents NOVIRA THERAPEUTICS, INC. 2015-06-04 — — US disclosed
US-20140179665-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 — — US disclosed
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 — — US disclosed
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 — — US disclosed
US-8629274-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2014-01-14 — — US disclosed
US-8629274-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2014-01-14 — — US disclosed
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-09-26 — — US disclosed
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-09-26 — — US disclosed
WO-2013096744-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152073-A1 Hepatitis B Antiviral Agents HAVCR2, EIF2AK2, IRF3 KMT2A 3528/4885MEN1 4246/4885CYP3A4 1962/4885
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 KMT2A 3528/4885MEN1 4246/4885CYP3A4 1962/4885
US-10196376-B2 Hepatitis B antiviral agents HAVCR2, EIF2AK2, IRF3 KMT2A 3528/4885MEN1 4246/4885CYP3A4 1962/4885
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 KMT2A 3528/4885MEN1 4246/4885CYP3A4 1962/4885
US-20140179665-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 KMT2A 3528/4885MEN1 4246/4885CYP3A4 1962/4885
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 KMT2A 3528/4885MEN1 4246/4885CYP3A4 1962/4885
US-20150259324-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 KMT2A 3528/4885MEN1 4246/4885CYP3A4 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.